QSAM Biosciences, Inc. (QSAM)

OTCMKTS: QSAM · Delayed Price · USD
5.82
0.01 (0.17%)
May 18, 2022 4:00 PM - Market closed
Market Cap9.67M
Revenue (ttm)n/a
Net Income (ttm)-11.98M
Shares Out1.66M
EPS (ttm)-17.12
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,500
Open5.80
Previous Close5.81
Day's Range5.50 - 5.82
52-Week Range0.35 - 20.40
Beta2.62
Analystsn/a
Price Targetn/a
Earnings Daten/a

About QSAM

QSAM Biosciences, Inc. engages in developing various nuclear medicines for the treatment of cancer and related diseases. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage bone targeting radiopharmaceutical. It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020. QSAM Biosciences, Inc. was incorporated in 2004 and is headquartered in Austin, Texas.

IndustryBiotechnology
Founded2004
CEOKevin Bolin
Employees4
Stock ExchangeOTCMKTS
Ticker SymbolQSAM
Full Company Profile

News

QSAM Biosciences Doses First Patient in its Clinical Trial for Cyclosam®, Radiopharmaceutical Drug Candidate for the ...

Austin, TX, April 28, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®), for t...

2 weeks ago - GlobeNewsWire

QSAM Biosciences Announces Reverse Stock Split Effective March 10, 2022

Austin, Texas, March 09, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc. (the “Company”) (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTM...

2 months ago - GlobeNewsWire

QSAM Biosciences Receives Rare Pediatric Disease Designation from FDA for CycloSam in the Treatment of Osteosarcoma

Austin, TX, Feb. 02, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®), for th...

3 months ago - GlobeNewsWire

QSAM Biosciences Appoints Adriann Sax to Board of Directors

Austin, TX, Jan. 25, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®), for th...

3 months ago - GlobeNewsWire

QSAM Biosciences Activates Clinical Sites and Opens Enrollment for its Phase 1 Clinical Trial of CycloSam® for the Tr...

Austin, TX, Dec. 01, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®), for th...

5 months ago - GlobeNewsWire

QSAM Biosciences Announces FDA Clearance of IND for Samarium-153 DOTMP (CycloSam®), an Investigational Radiopharmaceu...

Austin, TX, Aug. 25, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines, including Samarium-153 DOTMP (CycloSam®), for the treatment of ...

8 months ago - GlobeNewsWire

QSAM Biosciences Receives Patents in Japan and Canada; Strengthens Licensed IP Portfolio in Key Markets

Palm Beach, FL, Aug. 11, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines, including Samarium-153-DOTMP (CycloSam®), for the treatment...

9 months ago - GlobeNewsWire

QSAM Biosciences Issues Letter from CEO on Successful First Quarter 2021

Austin, TX, May 25, 2021 (GLOBE NEWSWIRE) -- The Chief Executive Officer of Q SAM Biosciences Inc. (OTCQB: QSAM), Douglas Baum, provided the following letter to shareholders today:

11 months ago - GlobeNewsWire

QSAM Biosciences Announces Submission of IND Application for CycloSam® with FDA

Austin, TX, May 04, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation nuclear medicines for the treatment of cancer and related diseases, announced today...

1 year ago - GlobeNewsWire

QSAM Biosciences Issues Letter from CEO on Successful Achievements and Future Milestones for Company

Austin, TX, April 19, 2021 (GLOBE NEWSWIRE) -- The Chief Executive Officer of Q SAM Biosciences Inc. (OTCQB: QSAM), Douglas Baum, provided the following letter to shareholders today:

1 year ago - GlobeNewsWire

QSAM Biosciences Seeks to Expand Radiochemical Assets; Signs Option Agreement to License its Second Promising Cancer ...

Austin, Texas, March 17, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc. (OTCQB: QSAM) announced today that it has signed an Exclusive Option Agreement with IsoTherapeutics Group, LLC to allow the Compa...

1 year ago - GlobeNewsWire

QSAM Biosciences Clarifies Recent Promotional and Trading Activities at the Request of OTC Markets

Austin, Texas;, Feb. 11, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM) (“QSAM” or the “Company”), today announced that it became aware on February 9, 2021 of certain promotional activitie...

1 year ago - GlobeNewsWire

QSAM Biosciences Closes Series B Preferred Private Placement; $2.5 Million in New Capital to Fund Upcoming Clinical T...

Austin, Texas, Jan. 28, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation nuclear medicines for the treatment of cancer and related diseases, announced t...

1 year ago - GlobeNewsWire

QSAM Biosciences Receives Favorable Safety Results in Study for its Leading Radiopharmaceutical Drug Candidate

Palm Beach, FL, Jan. 21, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines for the treatment of cancer and related diseases and conditi...

1 year ago - GlobeNewsWire